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Abstract
Background
The comparative performance of different drug-eluting stents (DES) among female patients
has not been assessed in a randomized manner.
Objectives
The SPIRIT Women Clinical Evaluation trial compared the durable polymer everolimus-elut-
ing XIENCE stent (DP-EES) with the durable polymer sirolimus-eluting Cypher stent (DP-
SES) in women undergoing percutaneous coronary intervention (PCI).
Methods
A total of 455 female patients with stable CAD were randomly assigned to receive DP-EES
(n = 304) or DP-SES (n = 151). The powered angiographic outcome of the trial was in-stent
late lumen loss (LLL) at 9 months after the index procedure. Secondary angiographic end
points included in-segment LLL, in-stent and in-segment binary restenosis and percent
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diameter stenosis. The primary clinical outcome was a composite of all-cause death, myo-
cardial infarction (MI) or target vessel revascularization (TVR).
Results
At 9-month follow-up, in-stent LLL was 0.19±0.38 mm and 0.11±0.37 mm in patients
assigned to DP-EES and DP-SES, respectively. The one-sided upper 95% CI of the differ-
ence in in-stent LLL between the groups of 0.08 mm was 0.15 and therefore within the pre-
specified non-inferiority margin of 0.17 mm (p for non-inferiority = 0.013). However, the test
for superiority showed a borderline significant difference in terms of LLL between DP-EES
and DP-SES (p for superiority = 0.044). There were no significant differences in binary reste-
nosis (2.0% vs. 0.72%, p = 0.44) and percent diameter stenosis (14.97±12.17 vs. 13.36
±10.82, p = 0.19). The rate of definite stent thrombosis at 12 months was lower in patients
treated with DP-EES (0% vs. 2.0%, p = 0.036).
Conclusions
Among women undergoing PCI, DP-EES was associated with a small but probably clinically
relevant increase in in-stent LLL at 9 months as compared to DP-SES and with a lower risk
of definite stent thrombosis at 12 months.
Trial registration
ClinicalTrials.gov NCT01182428.
https://clinicaltrials.gov/
Introduction
Early-generation drug-eluting stents (DES) reduced the need for repeat revascularization com-
pared with bare-metal stents (BMS) at the expense of an increased risk of very late stent throm-
bosis.[1, 2] New-generation DES were conceived to improve vascular healing after stent
implantation. Large scale randomized trials and meta-analyses showed better outcomes with
new-generation DES compared with BMS and early-generation DES.[3–5] In these studies,
however, female patients were typically underrepresented.[6, 7] Advanced age, atypical symp-
toms at presentation, higher burden of comorbidities and inadequate awareness of disease,
indeed, are factors that usually prevent an adequate proportion of female patients with coro-
nary artery disease (CAD) to participate into randomized trials.[8] Furthermore a tendency to
use less effective treatment in female relative to male patients with CAD has been reported. [9]
As consequence, treatment decisions are frequently based on overall outcomes. This is also the
case for the evaluation of coronary stents. Although available evidence supports a similar per-
formance of new-generation DES among female and male patients, [10, 11] no study has for-
mally compared a new-generation DES with an early-generation DES in female patients.
In this context, the Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent
System in the Treatment of Women with de novo Coronary Artery Lesions (SPIRIT Women)
represents a systematic attempt to evaluate the performance of the durable polymer everoli-
mus-eluting (DP-EES) Xience stent in a population of female patients with CAD undergoing
percutaneous coronary intervention (PCI).[12] The results of the principal non-randomized
The SPIRIT WOMEN randomized study
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cohort have been previously reported.[13] Here, we reported the results of the randomized
study comparing the angiographic outcomes of DP-EES with the durable polymer sirolimus
eluting (DP-SES) Cypher stent.
Material and methods
Study population
The design of the SPIRIT Women study was reported elsewhere.[12, 13] The trial was con-
ceived as a substudy of the main SPIRIT Women study that was registered in 2007 (NCT
00496938). Subsequent changes in the original protocol were made and the randomized study
was registered a separate one in 2010 (NCT01182428). Complete study protocol is available
among Supporting Information files (S1 Study Protocol).
455 female patients admitted for PCI at 25 centers (22 in Europe and 3 in South America),
between September 2008 and December 2009, were randomly assigned (2:1) to receive
DP-EES (Xience V and Xience Prime, Abbott Vascular, Santa Clara, CA, USA) or DP-SES
(Cypher Select, Cordis, Miami Lakes, Florida, USA). The trial was funded by Abbott Vascular.
The study complied with the declaration of Helsinki and was approved by the institutional
review board at each participating center (S1 Table). Eligible patients provided written,
informed consent.
Inclusion and exclusion criteria
Female patients, aged >18 years of age, with evidence of myocardial ischemia (e.g., stable or
unstable angina, silent ischemia, positive functional study or a reversible change in the electro-
cardiogram consistent with ischemia) were eligible in presence of significant de novo coronary
artery lesions. They had to be acceptable candidate for coronary artery bypass graft (CABG)
surgery and agree to undergo all follow-up examinations. Angiographic inclusion criteria
included: de novo coronary lesions (no prior stent implant, no prior brachytherapy) with ref-
erence diameter between 2.5 mm and 4.0 mm and 28 mm in length by visual estimate.
There were no limitations in the number of involved vessels; however, interventions were lim-
ited to a maximum of 4 planned study stents. The most important exclusion criteria were the
participation in another device or drug study or the completion of the follow-up phase of
another study within the previous 30 days.
Study devices
The XIENCE V (DP-EES) (Abbott Vascular, Santa Clara, CA, USA) is a cobalt chromium
stent with durable polymeric coating consisting of acrylic and fluoropolymers eluting everoli-
mus. At the time of this study, it was available in diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm
and lengths of 8, 12, 15, 18, 23, 28 mm. The XIENCE PRIME stent system (Abbott Vascular,
Santa Clara, CA, USA) was also used where available. It featured longer cell length, taller non-
linear links for improved flexibility, straighter bar arms to reduce strut interference and to bet-
ter maintain coating integrity during the crimping process, and a modified proximal end ring
to reduce strut lifting. The active control device was the durable polymer sirolimus-eluting
Cypher stent (Cordis, Johnson & Johnson, Warren, NJ, USA)(DP-SES) consisting of sirolimus
incorporated in an amalgam of two biostable polymers.
Both the DP-EES and DP-SES can have two workhorse designs, one ranging from 2.25 to
3.0mm and another covering 3.5 and 4.0 mm diameters. Furthermore, they showed compara-
ble capacity to be overexpanded well above their labelled maximal diameter. Specifically, a
maximal expansion of 4.4 mm and 4.7 mm for the Xience DP-EES and the Cypher DP-SES
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stents ranging from 2.25 to 3.00 mm of diameter were reported, respectively. For larger stents
(3.50 to 4.0mm) the maximal capacity expansion was 5.6 mm and 5.8 mm for DP-EES and
DP-SES, respectively.[14]
Quantitative coronary angiography
Baseline and follow-up angiograms were collected in accordance with the Angiographic Core
Laboratory requirements and analyzed by technicians blinded to treatment assignments and
clinical outcomes.
Quantitative measurements included: reference vessel diameter, RVD, minimal luminal
diameter, MLD, average of two orthogonal views of the narrowest point within the area of
assessment–in lesion, in stent or in segment; percent diameter stenosis, calculated as 100 
(1—MLD/RVD) using the mean values from two orthogonal views; late lumen loss (LLL), cal-
culated as difference between minimal lumen diameter after the procedure and minimal
lumen diameter at angiographic follow-up at 9 months. Binary restenosis was defined as steno-
sis of50% of the MLD in the target lesion at the time of angiographic follow-up. All measure-
ments were obtained within the stented segment (in-stent) and over the entire segment
comprising the stent and its 5 mm proximal and distal margins (in-segment).
Procedures and follow-up
After confirmation of clinical and angiographic inclusion criteria and prior to PCI, patients
were randomly allocated (2:1), achieving concealment of allocation by an interactive voice
response system, to treatment with DP-EES or DP-SES. Randomization was stratified by dia-
betes mellitus, and lesion characteristics (complex vs non-complex, where complex was
defined as treatment of three vessels, two lesions within one vessel, lesions involving aorto-
ostial locations, bifurcations lesions with side branches 2 mm in diameter or stenosis involv-
ing the ostium of side branches). A target lesion was defined as any lesion to be treated at the
time of the index procedure. The treatment strategy was determined by the investigator. If two
or more target lesions had to be treated, all lesions received the device as assigned by randomi-
zation. Similarly, if any staged procedures were planned or bailout or additional stenting were
needed, the same stent as allocated by randomization for the index procedure had to be used.
Peri-procedural antiplatelet therapy included a loading dose of clopidogrel (300 mg) and
acetylsalicylic acid (75 mg). The choice of appropriate anticoagulants (unfractionated hepa-
rin or bivalirudin) as well as the use of glycoprotein IIb/IIIa inhibitors were left to the discre-
tion of the investigator. Patients were maintained on dual antiplatelet therapy with clopidogrel
bisulfate 75 mg daily for a minimum of six months after the procedure. Angiographic follow-
up was performed at 270 days (9 months) ± 14 days. Clinical follow-up was planned at 30 days,
240 days, and 365 days after the procedure, and patients were questioned about the occurrence
of angina or any adverse events. Adverse events were independently adjudicated by a clinical
event committee consisting of blinded cardiologists.
Study endpoints and definitions
The powered angiographic outcome of the trial was in-stent LLL at 9 months after the index
procedure as assessed by quantitative coronary angiography. Secondary angiographic end
points included in-segment LLL, in-stent and in-segment binary restenosis and percent diam-
eter stenosis. The primary clinical outcome, which was descriptive in nature, was a composite
of all-cause death, myocardial infarction (MI) or target vessel revascularization (TVR). Sec-
ondary clinical outcomes were the components of the primary outcome, cardiac death, target
lesion revascularization (TLR), target lesion failure (TLF) defined as the composite of cardiac
The SPIRIT WOMEN randomized study
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death, target-vessel MI, and ischemia-driven TLR and definite and probable stent thrombosis.
According to Academic Research Consortium criteria, (1) all deaths were considered cardiac
unless an unequivocal non-cardiac cause was established. Any death due to proximate cardiac
cause, unwitnessed death and death of unknown cause, and all procedure-related deaths,
including those related to concomitant treatment, were classified as cardiac death. Myocardial
infarction (MI) was defined as follows: for non-procedural/spontaneous MI, troponin or crea-
tine kinase muscle and brain (CK-MB) levels had to be>2 times the upper limit of normal; for
peri-procedural MI, troponin or CK-MB levels had to be3 times the upper limit of normal.
The peri-procedural period included the first 48 hours and 72 hours after PCI and CABG,
respectively. All late events that were not associated with revascularization procedures were
considered spontaneous. TLR was defined as any repeat percutaneous intervention of the tar-
get lesion or bypass surgery of the target vessel performed for restenosis or other complications
of the target lesion. The target lesion was defined as the treated segment from 5 mm proximal
and 5 mm distal to the stent. TVR was defined as any repeat percutaneous intervention or sur-
gical bypass of any segment of the target vessel. Stent thrombosis was defined on the basis of
the Academic Research Consortium criteria. Clinical device success was defined as successful
delivery and deployment of the study stent at the intended target lesion and successful with-
drawal of the stent delivery system with attainment of final residual stenosis of less than 50% of
the target lesion by visual estimation, without use of a device outside the assigned treatment
strategy. Clinical procedure success was defined as successful delivery and deployment of the
study stent or stents at the intended target lesion and successful withdrawal of the stent deliv-
ery system with attainment of final residual stenosis of less than 50% by visual estimation,
using any adjunctive device without the occurrence of cardiac death, MI attributed to the tar-
get vessel or TLR during the hospital stay with a maximum of first seven days post index
procedure.
Statistical analysis
The study was designed as a non-inferiority trial powered for the pre-specified primary angio-
graphic endpoint in-stent LLL at 9 months. Sample size calculation for the primary endpoint
was based on the following assumptions: One-sided non-inferiority test with α = 5% and
power = 90%, 2:1 randomization ratio (EES:SES), in-stent LLL equal in both arms with a com-
mon standard deviation of 0.53 mm, and a non-inferiority margin δ = +0.17 mm (difference
defined as LLLEES minus LLLSES). Given the above assumptions, a total of 378 subjects were
required. To account for dropouts at angiographic follow-up, 450 subjects were enrolled.
The non-inferiority p-value for the angiographic primary outcome was one-sided and
derived from a Z-test that compared the difference between groups against the non-inferiority
margin. For ease of interpretation, all other p-values and 95% confidence intervals are two-
sided, for superiority. Since the two-sided 95% confidence interval of the primary endpoint
excluded the line of no difference, we also calculated two-sided p-values for superiority for the
primary endpoint.[15]
Continuous variables were expressed as mean ± standard deviations (SD) and compared
with t-test; categorical variables were summarized as frequencies (%) and compared with Chi-
square test or Fisher’s exact test if the expected number of events was below 5 per cell. p-values
were derived from general or generalized linear mixed models that account for the correlation
of multiple lesions within patients. The Mantel–Cox method was used to compare outcomes
between patients randomized to DP-SES or DP-EES, reporting rate ratios (RRs) with 95% con-
fidence intervals (CI). In case of zero events in any comparator group, we reported continuity
corrected risk ratios with p-values from Fisher’s exact tests. All patients who underwent
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randomization were included in the analysis of primary and secondary outcomes in the groups
to which they were originally allocated to, regardless of the treatment actually received (inten-
tion-to-treat principle). No adjustments were made for multiple comparisons. Analyses were
performed by a statistician of an academic clinical trials unit (CTU Bern, Bern University Hos-
pital, Switzerland) with Stata 13 (Stata, Inc., College Station, TX, USA).
Results
A total of 455 patients were randomly assigned to undergo treatment with DP-EES (304
patients, 423 lesions) or DP-SES (151 patients, 200 lesions). The flow diagram of patients
included in the trial is shown in Fig 1. Baseline clinical characteristics are reported in Table 1.
The majority of patients in both arms had stable CAD with a high prevalence of cardiovascular
risk factors. Angiographic and procedural features are summarized in S2 Table and were simi-
lar for both groups with the exception of three-vessel treatment that was more common in
patients assigned to DP-EES. Clinical procedure success (88.2% vs. 87.4%, p = 0.88) and device
success (99.3% vs. 99.5%, p = 1.00) were not different between groups.
Fig 1. Flow diagram of patients included in the trial (according to CONSORT 2010). A total of 455 patients were randomly assigned to treatment with
DP-EES (304 patients) or DP-SES (151 patients). Number of patients assessed for elegibility was not available. DP-EES, Durable polymer-everolimus eluting
stent; DP-SES, Durable polymer-sirolimus eluting stent.
https://doi.org/10.1371/journal.pone.0182632.g001
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Angiographic outcomes
At 9 months, 219 patients in the DP-EES group (72%) and 110 patients in the DP-SES group
(73%) underwent angiographic follow-up. As shown in S3 Table, baseline patient characteris-
tics were comparable between arms for this subset of patients. There were not significant dif-
ferences between both groups for angiographic measurements immediately after the index
procedure (Table 2). At 9-month follow-up, in-stent LLL was 0.19±0.38 mm and 0.11±0.37
mm in patients assigned to DP-EES and DP-SES, respectively. The one-sided upper 95% CI of
the difference in in-stent LLL between the groups of 0.08 mm was 0.15 and therefore within
the pre-specified non-inferiority margin of 0.17 mm (p for non-inferiority = 0.013). However,
the test for superiority showed a borderline significant difference in terms of LLL between
DP-EES and DP-SES (p for superiority = 0.044). Fig 2 reports the cumulative distribution of
the primary endpoint separately for the study devices. In-stent binary restenosis (2.0% vs.
0.72%, p = 0.44) and percent diameter stenosis (14.97%±12.17 vs. 13.36%±10.82, p = 0.19)
were similar between groups. In-segment LLL was 0.09±0.40 mm in the DP-EES group and
0.03±0.38 in the DP-SES group (p = 0.166). In-segment binary restenosis was 3.3% and 2.2%,
respectively (p = 0.76). Fig 3 shows the stratified analysis for the primary endpoint in several
subgroups without significant differences in the pre-specified subsets of patients with diabetes
and patients with complex lesions.
Table 1. Baseline clinical characteristics.
DP-EES DP-SES
n = 304 n = 151
Age 68.3 ± 10.1 69.8 ± 10.6
Waist circumference (cm) 93.8 ± 15.2 93.8 ± 15.2
BMI (kg/m2) 27.5 ± 5.1 27.4 ± 5.5
Current tobacco user 52 (17.4%) 24 (16.3%)
Postmenopausal status 284 (94.4%) 144 (95.4%)
Hypertension 253 (83.5%) 130 (86.1%)
Lipid disorder 224 (73.7%) 111 (74.0%)
Diabetes Type II 74 (24.3%) 41 (27.2%)
Oral hypoglycemic 46 (62.2%) 21 (51.2%)
Insulin 19 (25.7%) 12 (29.3%)
Previous PCI 60 (19.8%) 31 (20.7%)
Previous MI 79 (26.1%) 31 (20.7%)
MI within 2 months of screening date 27 (34.2%) 10 (32.3%)
Family history of premature CAD 109 (35.9%) 55 (36.4%)
Clinical presentation
Stable angina 152 (50.2%) 81 (54.0%)
Unstable angina 116 (38.3%) 48 (32.0%)
Silent ischemia 35 (11.6%) 21 (14.0%)
Left ventricular dysfunction 43 (15.6%) 19 (14.6%)
Anginal symptoms
Typical angina 234 (77.5%) 119 (78.8%)
Atypical chest pain 31 (10.3%) 14 (9.3%)
No chest pain 37 (12.3%) 18 (11.9%)
Data expressed as n (%) or means ± standard deviations. BMI, Body mass index; CAD, Coronary artery disease; DP-EES, Durable polymer- everolimus
eluting stents; DP-SES, Durable polymer- sirolimus eluting stents; MI, Myocardial infarction; PCI, Percutaneous coronary intervention
https://doi.org/10.1371/journal.pone.0182632.t001
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Clinical outcomes
At one year, clinical follow-up was available in 286 DP-EES (94%) and 142 DP-SES (94%)
patients. As shown in S1 Fig, DAPT use was similar in both groups throughout the 1-year fol-
low-up (p = 0.67). Clinical outcomes are reported in Table 3. The composite endpoint of
death, MI or TVR occurred in 20.7% and 21.9% of patients in the DP-EES and DP-SES group,
respectively (risk ratio 0.93; 95% CI 0.61–1.43, p = 0.75). Rates of TLF (15.3% vs. 17.3%, risk
ratio 0.87, 95% CI 0.54–1.41, p = 0.57), MI (11.2% vs. 13.3%, risk ratio 0.83; 95% CI 0.48–1.45,
p = 0.50), and clinically-indicated TLR (5.1% vs. 5.5%, risk ratio 0.93, 95% CI 0.40–2.20,
p = 0.88) were similar in both groups (S2 Fig). Overall, three cases of definite ST were reported
Table 2. Quantitative coronary angiography analysis after index procedure and at 9-month follow-up.
DP-EES DP-SES Difference (95%-CI) [EES-SES] p value
N. Patients 219 110
N. Lesions 300 140
After index procedure*
Stent length (mm) 19.0 ± 9.29 18.3 ± 7.10 0.71 (-1.11 to 2.52) 0.44
Segment length (mm) 26.92 ± 9.50 26.65 ± 7.71 0.31 (-1.55 to 2.17) 0.74
Diameter Stenosis (%)
In-stent 9.11 ± 6.57 10.12 ± 8.80 -1.02 (-2.54 to 0.49) 0.18
In-segment 17.99 ± 8.21 17.94 ± 9.50 -0.08 (-1.86 to 1.70) 0.92
RVD (mm)
In-stent 2.76 ± 0.45 2.77 ± 0.45 -0.02 (-0.11 to 0.08) 0.72
In-segment 2.64 ± 0.49 2.67 ± 0.50 -0.02 (-0.13 to 0.08) 0.65
MLD (mm)
In-stent 2.50 ± 0.41 2.50 ± 0.47 0.00 (-0.09 to 0.09) 0.96
In-segment 2.17 ± 0.48 2.19 ± 0.51 -0.02 (-0.12 to 0.08) 0.72
At 9-month follow-up*
Stent Length (mm) 19.27 ± 9.56 18.92 ± 8.53 0.49 (-1.48 to 2.45) 0.62
Segment Length (mm) 27.24 ± 9.66 26.98 ± 8.43 0.36 (-1.60 to 2.31) 0.72
Diameter Stenosis (%)
In-stent 14.97 ± 12.17 13.36 ± 10.82 1.63 (-0.82 to 4.08) 0.19
In-segment 21.73 ± 12.43 20.09 ± 12.60 1.65 (-0.89 to 4.19) 0.20
RVD (mm)
In-stent 2.72 ± 0.44 2.75 ± 0.47 -0.03 (-0.13 to 0.06) 0.52
In-segment 2.66 ± 0.46 2.69 ± 0.50 -0.03 (-0.13 to 0.07 0.59
Binary Restenosis (%)**
In-stent 6 (2.0%) 1 (0.72%) 0.44
In-segment 10 (3.3%) 3 (2.2%) 0.76
MLD (mm)
In-stent 2.31 ± 0.53 2.39 ± 0.51 -0.08 (-0.19 to 0.03) 0.15
In-segment 2.08 ± 0.49 2.16 ± 0.56 -0.08 (-0.18 to 0.03) 0.16
LLL (mm)
In-stent 0.19 ± 0.38 0.11 ± 0.37 0.08 (0.00 to 0.16) 0.044
In-segment 0.09 ± 0.40 0.03 ± 0.38 0.06 (-0.02 to 0.14) 0.16
* Analysis based on subset of serial lesions, i.e. with post-procedural and follow-up angiography available. Two-sided p-values and CIs from linear mixed
models (LMM) with random intercepts at level of patients. Non-inferiority p-value is one-sided from a Z-test constructed from the LMM-based standard error
of the difference.
**p-value from Fisher’s exact test. LLL, Late lumen loss; MLD, Minimal luminal diameter; RVD, Reference vessel diameter.
https://doi.org/10.1371/journal.pone.0182632.t002
The SPIRIT WOMEN randomized study
PLOS ONE | https://doi.org/10.1371/journal.pone.0182632 August 10, 2017 8 / 16
among patients allocated to DP-SES. One patient died for an acute ST; a second one died as
consequence of subacute ST (6 days after the procedure) and the third one experienced a late,
non-fatal ST after premature DAPT discontinuation. No definite ST was documented in
patients allocated to DP-EES. Thus, the cumulative incidence of definite ST at 1-year was 2.0%
and 0% in patients assigned to DP-SES and DP-EES, respectively (p = 0.036) (S4 Table).
Discussion
The main findings of this randomized trial comparing DP-EES with DP-SES in a female popu-
lation undergoing PCI were as follows:
• Even though DP-EES was formally non-inferior to DP-SES with respect to the primary end-
point of LLL, superiority testing suggested a borderline significant advantage of DP-SES
over DP-EES, with no significant differences between groups on other measures of angio-
graphic performance.
• The clinical efficacy of DP-EES appeared similar to the DP-SES, but there was an improved
safety due to a lower risk of stent thrombosis with DP-EES.
This study represents the first randomized comparison between DES among female
patients. Potential mechanisms by which female sex could affect the outcome after PCI include
different clinical and angiographic characteristics and a different distribution of cardiovascular
risk factors. [16, 17]
Safety and efficacy profiles of DES were established largely independently of gender.[11, 18]
However, evidence of the comparative performance of early- and new- generation DES is
sparse and based on retrospective or post hoc analyses. In the female cohort of the SORT OUT
IV trial (Randomized Clinical Comparison of the Xience V and the Cypher Coronary Stents in
Non-selected Patients With Coronary Heart Disease), DP-EES had similar rates of major
adverse cardiac events compared with DP-SES at 18 months (6.3% vs 7.9%, respectively, p = 0
.47).[19] In contrast, a retrospective registry including 1,649 women reported a significantly
Fig 2. Cumulative distribution of the primary end point in-stent late lumen loss shown separately for
the two stent types. DP-EES, Durable polymer-everolimus eluting stent = solid line; DP-SES, Durable
polymer-sirolimus eluting stent = dashed line.
https://doi.org/10.1371/journal.pone.0182632.g002
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lower rate of major adverse cardiac events in DP-EES compared with DP-SES at 1-year (10.8%
vs 14.7%, p = 0.04).[20] Against this background, the present study provides the first random-
ized evidence of angiographic performance of DP-EES compared with DP-SES in female
patients. Our results corroborate the findings of previous studies not restricted to female
patients. In the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss
After Stenting) trial, DP-EES were formally found non inferior to DP-SES in terms of
9-month in-segment and in-stent LLL (0.11±0.38 mm vs. 0.06±0.36 mm, p for non-inferior-
ity = 0.0382 and 0.19±0.35 mm vs. 0.15±0.34 mm, p for non-inferiority = 0.012, respectively),
Fig 3. Stratified analysis of in-stent late lumen loss (LLL). Two-sided p-values and CIs from linear mixed models with random intercepts at level of
patients. BMI, Body mass index; DP-EES, Durable polymer- everolimus eluting stents; DP-SES. Durable polymer-sirolimus eluting stent; LAD, Left anterior
descending artery; RVD, Reference vessel diameter.
https://doi.org/10.1371/journal.pone.0182632.g003
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with trends towards a slightly higher LLL with DP-EES, concordant with our trial.[21] Simi-
larly, the angiographic sub-study of the RESET trial (Randomized Evaluation of Sirolimus-
eluting versus Everolimus eluting stent Trial) enrolling 571 patients demonstrated the non-
inferiority of DP-EES relative to DP-SES in terms of in-segment LLL (0.06±0.37 mm vs. 0.02
±0.46 mm, p for non-inferiority<0.001), again numerically with a slightly higher LLL for
DP-EES.[22] Table 4 lists other randomized trials that reported somewhat higher LLL with
second-generation DES as compared with DP-SES.[21, 23, 24] These angiographic results may
not reflect a lower angiographic efficacy of second generation DES, a decreased tendency for
pathological remodeling and an increased propensity to have a small, yet homogeneous neoin-
timal layer across the entire stent surface, which is likely to be protective against thrombotic
processes.[25] The notion that lesser angiographic LLL is always associated with better clinical
outcome, as found for bare-metal stents and early generation DES,[26] may therefore hold
true no longer. Angiographic data for second generation DES contrast with the wealth of clini-
cal data supporting an improved safety and efficacy of second generation DES over DP-SES.
[27] Intravascular imaging has the potential to improve our understanding of vascular
response to stent implantation. In this regard, optical coherence tomography-based studies
showed that DP-EES have the best performance in terms of struts apposition among other
early- and new-generation DES.[28]
Even though the DP-SES is no longer used in clinical practice, results of our trial are still
scientifically and clinically useful in that they can inform future network meta-analyses of both
angiographic and clinical outcomes in women with stable coronary artery disease. Such analy-
ses will typically include comparisons with first generation DP-DES to achieve best statistical
precision and allow careful exploration of inconsistency.[27]
Table 3. Clinical outcomes at 1 year follow-up.
DP-EES DP-SES Rate Ratio p value
n = 304 n = 151 (95% CI)
Death 3 (1.0%) 6 (4.0%) 0.25 (0.06 to 0.98) 0.06§
Cardiac death 2 (0.7%) 4 (2.7%) 0.25 (0.04 to 1.34) 0.09§
MI 39 (12.9%) 21 (13.9%) 0.91 (0.54 to 1.58) 0.73
Target vessel-MI 34 (11.2%) 20 (13.3%) 0.82 (0.46 to 1.48) 0.52
Any revascularization 51 (17.4%) 29 (19.9%) 0.87 (0.55 to 1.38) 0.56
Clinically-indicated revascularization 45 (15.3%) 23 (15.8%) 0.97 (0.59 to 1.61) 0.91
Any TVR 28 (9.6%) 17 (11.7%) 0.82 (0.45 to 1.49) 0.51
Clinically-indicated TVR 19 (6.5%) 14 (9.6%) 0.66 (0.33 to 1.33) 0.24
Any TLR 23 (7.8%) 12 (8.3%) 0.96 (0.48 to 1.93) 0.91
Clinically-indicated TLR 15 (5.1%) 8 (5.5%) 0.93 (0.40 to 2.21) 0.88
Target lesion failure * 46 (15.3%) 26 (17.3%) 0.87 (0.52 to 1.43) 0.57
Death, MI, TVR** 62 (20.7%) 33 (21.9%) 0.93 (0.60 to 1.44) 0.75
Stroke or TIA 3 (1.0%) 2 (1.4%) 0.74 (0.12 to 4.43) 0.66§
Definite ST 0 (0.0%) 3 (2.0%) 0.07 (0.00 to 1.35) 0.036§
Probable ST 0 (0.0%) 0 (0.0%) - -
Number of first events and percentages are reported. Rate ratios RR (95% CI) are estimated using the Mantel-Cox method with two-sided p-values from
log-rank test. Clinical outcomes analyzed on patient level. All events were censored beyond 365 days.
§p-value from 2 sided Fisher’s exact test.
*Cardiac death, TV-MI, clinically indicated TLR
**Primary endpoint.
MI, Myocardial infarction; ST, Stent thrombosis; TIA, Transient ischemic attack; TLR, Target lesion revascularization; TVR, Target vessel revascularization.
https://doi.org/10.1371/journal.pone.0182632.t003
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A lower rate of definite stent thrombosis as well numerically lower definite or probable
stent thrombosis events were reported in the DP-EES arm of our study. These observations are
in line with available randomized evidence. The SORT-OUT IV trial reported a significant
reduction in the risk of overall and very late stent thrombosis in patients assigned to DP-EES
compared with DP-SES at 3 years follow-up.[29] In a meta-analysis of 11 randomized trials,
Park and colleagues found a 54% relative reduction in the risk of definite stent thrombosis and
a 15% relative reduction in the risk of repeat revascularization among 12,869 patients treated
with DP-EES compared with DP-SES.[30] Moreover, network meta-analyses reported a lower
risk of stent thrombosis with the DP-EES compared with BMS and early-generation DES.[3,
31–33] In a pooled analysis including more than 11,000 female participants across 26 random-
ized trials, new-generation DES were associated with a significant reduction in the risk of stent
thrombosis and TLR compared with early-generation DES during the 1-year of follow-up.[11]
The findings of the present study have to be interpreted in view of several limitations. 1.The
comparison between new and early generation DES could be considered outdated as the
Cypher DP-SES is no longer commercially available for clinical use. This limitation suggests
that despite dedicated research efforts, appropriately designed trials in women occur at a later
stage of clinical research. 2. There was a significant delay between the end of the trial in May
2012 and its publication, which is explained by delays in execution of contracts for the data
analysis, which was outsourced by the sponsor to an academic clinical trials unit, two statisti-
cians sequentially leaving the unit unexpectedly for new positions before completing the analy-
ses, and a series of rejections of the submitted manuscript in view of the outdated nature of the
control device and the ambiguous findings of the trial. 3. The study was not powered to iden-
tify differences in clinical outcomes since the sample size was estimated on the basis of the
angiographic primary endpoint. 4. Patients with acute coronary syndromes were excluded
from the trial, and therefore our results may not be extrapolated to this patient population. 5.
A drop-out rate of approximately 30% for angiographic follow-up is relatively high compared
to other trials with primary angiographic outcome. 6. The rates of TLR were somewhat
increased compared with other randomized studies. Although female patients have generally a
higher risk profile, the angiographic follow-up may inflate the rates new revascularization
Table 4. Angiographic performance of DP-SES and second generation DES across randomized studies.
Late Lumen Loss
Study (Author, year) Nr. of Patients Second generation DES DP-SES p value
EXCELLENT (Park, 2011) DP-EES: 708 0.19±0.35 0.15± 0.34 0.09
DP-SES: 216
LONG-DES-III (Park, 2011) DP-EES: 224 0.17±0.41* 0.09±0.30* 0.042
DP-SES: 226
DiabeDES IV [23] DP-EES: 79 0.13±0.57** -0.05±0.62** 0.06
DP-SES: 77
ENDEAVOR III (Kandzari, 2006) DP-ZES: 323 0.34±0.44 0.13±0.32 < 0.001
DP-SES: 113
ISAR-TEST-2 (Byrne, 2010) DP-ZES: 339 0.58 ± 0.55 0.24±0.51 < 0.001
DP-SES: 335
Number of first events and percentages are reported. Rate ratios RR (95% CI) are estimated using the Mantel-Cox method with two-sided p-values from
log-rank test. All events were censored beyond 365 days. Continuity corrected RR with Fisher’s exact test for zero outcomes.
*Cardiac death, TV-MI, clinically indicated TLR
**Primary endpoint.
MI, Myocardial infarction; TIA, Transient ischemic attack; TLR, Target lesion revascularization; TVR, Target vessel revascularization.
https://doi.org/10.1371/journal.pone.0182632.t004
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procedures. However, the rate of clinically–indicated TLR is in line with previous trials investi-
gating the performance of DES in female patients. 7. Further iterations of the delivery system
of the Xience DP-EES were done in the last years (Xience Xpedition, XIENCE Alpine), even
though stent, drug coating formulation and drug dose density remained identical.
Conclusions
In the first randomized trial comparing two different DES among female patients undergoing
PCI, DP-EES was associated with a small increase in in-stent LLL at 9 months as compared to
DP-SES, but a lower risk of definite stent thrombosis at 12 months.
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